A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged ...
Think it's time for a booster? Moderna says its newest COVID vaccine is showing signs of a stronger immune response against the virus than the current shot being offered and a longer shelf-life.
Moderna Inc. announced Tuesday that its next-generation COVID vaccine produced better immune results in a late-stage trial than its previous vaccines, and will be a key part of its combination ...
Shares of Moderna (MRNA) are moving up on Tuesday afternoon after the company released positive data for its individualized cancer vaccine tested in combination with Merck's Keytruda (MRK).
Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government ...
On Thursday, investment firm Jefferies updated its outlook on Moderna (NASDAQ:MRNA) shares, raising the price target to $125 from the previous $115. The firm has maintained a Hold rating on the ...
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints ...
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low. Moderna says its updated coronavirus ...
In the U.S., for every 100,000 people 23 people are diagnosed with melanoma each year and two people die from it. Texas Oncology is hoping to enroll 10 to 15 patients in the melanoma vaccine trial.
Covid vaccines will be sold on the high street for the first time for just under £100 to those ineligible for free jabs on the NHS. Boots is set to become the first major pharmacy to offer the ...
On Thursday, investment firm Jefferies updated its outlook on Moderna (NASDAQ:MRNA) shares, raising the price target to $125 from the previous $115. The firm has maintained a Hold rating on the NASDAQ ...